Angle (AGL)
market vs.
industry GROWTH & VALUE
| Trailing 12m | ||||
| PE Ratio (ttm) | n/a |
|
|
|
| PEG Ratio (ttm) |
|
|
||
| EPS Growth (ttm) | % |
|
|
|
| Dividend Yield (ttm) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 4.39 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 30th Apr | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | TTM | 2013E | 2014E | CAGR / Avg | |
| Revenue | £m | ||||||||||
| Operating Profit | £m | ||||||||||
| Net Profit | £m | ||||||||||
| EPS Reported | p | ||||||||||
| EPS Normalised | p | ||||||||||
| EPS Growth | % | ||||||||||
| PE Ratio | x | ||||||||||
| PEG | x | ||||||||||
| Profitability | |||||||||||
| Operating Margin | % | ||||||||||
| ROA | % | ||||||||||
| ROCE | % | ||||||||||
| ROE | % | ||||||||||
| Cashflow | |||||||||||
| Op. Cashflow ps | p | ||||||||||
| Capex ps | p | ||||||||||
| Free Cashflow ps | p | ||||||||||
| Dividends | |||||||||||
| Dividend ps | p | ||||||||||
| Dividend Growth | % | ||||||||||
| Dividend Yield | % | ||||||||||
| Dividend Cover | x | ||||||||||
| Balance Sheet | |||||||||||
| Cash etc | £m | ||||||||||
| Working Capital | £m | ||||||||||
| Net Fixed Assets | £m | ||||||||||
| Net Debt | £m | ||||||||||
| Book Value | £m | ||||||||||
| Average Shares | m | ||||||||||
| Book Value ps | p | -10.4% | |||||||||
FINANCIAL BRIEF: For the six months ended 31 October 2012, ANGLE plc revenues decreased 37% to L467K. Net loss decreased 85% to L269K. Revenues reflect Consulting and Management decrease of 35% to L430K, Ventures decrease of 7% to L37K. Lower net loss reflects Change in fair value decrease from L1.3M (expense) to L286K (income), Management services decrease of 19% to L502K (expense), Controlled investments decrease of 20% to L322K (expense). more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 31st Oct '12) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: | 0 | 0 | 0 | 1 | 0 |
ANGLE plc (ANGLE) is a holding commercially driven specialist medical diagnostic company with pioneering products in cancer diagnostics and foetal health. The Company’s principal subsidiaries are Parsortix Inc (Parsortix) and Novocellus Limited, which are commercially driven specialist medical diagnostics companies with pioneering products in cancer diagnostics and foetal health. ANGLE also owns a major investment in Geomerics Limited, a business with a computer graphics technology platform, and a specialist technology consultancy. The Company operates in four segments: Controlled investments in medical diagnostics, Non-controlled investments, Ventures and Management services. ANGLE has developed its Parsortix technology to capture circulating tumor cells (CTCs) in cancer patient blood.
Directors: Andrew Newland (CEO) , Ian Griffiths (Fin. Dir.) ,
No. of Employees: 37 No. of Shareholders: n/a
| Last Annual | April 30th, 2012 |
| Last Interim | October 31st, 2012 |
| Shares in Issue | 40,717,059 |
| Free Float | 23.4m (57.6%) |
| Sector | Industrials |
| Industry | Professional & Commercial Services |
| Index | FTSE Aim All Share, |
| Exchange |
London Stock Exchange (AIM) |
| Eligible for | an ISA? a SIPP? |
| Address | Surrey Research Park,3 Frederick Sanger Road, Guildford, GUILDFORD, GU2 7YD, United Kingdom |
| Web | http://www.angleplc.com |
| Phone | +44 1483 685830 |
| Contact | Ian F Griffiths (Secy.,) |
| Registrar | CRG Capita |
| Auditors | Baker Tilly UK Audit LLP |
| 14th May | News |
| 13th May | PARSORTIX CELL HARVESTING |
| 7th May | Parsortix Regulatory Approval Update |
| 3rd May | News |
| 28th Feb | Parsortix Research Product Launch |
| 15th Feb | Directors share transfer |
Recent ↓
